Introduction {#Sec1}
============

Bronchoprovocation challenge is a critical tool in the diagnosis and monitoring of asthma. One of the first standardized methacholine challenge testing (MCT) protocol proposed a five-breath dosimeter protocol with a fixed initial methacholine dose followed by doubling increments in methacholine concentration until the provocation concentration causing a 20% decline (PC~20~) in forced expiratory volume in 1 s (FEV~1~) was reached or until the test was over \[[@CR1]\]. Although safe and accurate, this protocol could be exhausting for patients and time-consuming for both patients and technicians. In the last decades, many protocol variations aiming at simplifying and shortening MCTs were proposed, such as the 2-min tidal breathing dosing method, the optional use of a higher initial dose of methacholine and the skipping of the next methacholine dose when FEV~1~ fell by \< 5% of its baseline level \[[@CR2]\]. These variations were shown to be safe, while maintaining diagnostic precision \[[@CR2]--[@CR5]\].

In order to further simplify and shorten MCTs, other methods have also been described in more recent years, such as using threefold skips in methacholine concentration \[[@CR6]\], the use of 2-tiered protocols \[[@CR7]\] or the early stopping of the test when PC~10~, rather than PC~20~, was reached at a methacholine dose of ≤ 1 mg/ml \[[@CR8]\]. These changes made to the traditional MCT protocol offer the advantage of potentially decreasing test duration, while maintaining diagnostic precision and safety.

Current guidelines suggest the omission of the next methacholine dose if FEV~1~ falls by less than 5% of its previous value \[[@CR2]\]. The use of a higher threshold for dose omission may further allow the test to be shortened and simplified. In our own center, we implemented the use of a \< 10% threshold to allow the skipping of a methacholine dose in an attempt to decrease the overall duration of the test, but the safety and efficacy of this measure has not been formally studied yet. We therefore designed the following study to assess the safety and feasibility of using a 10% fall in FEV~1~ (as opposed to 5%) as a threshold to skip the next dose of methacholine in patients undergoing MCT.

Methods {#Sec2}
=======

This is a retrospective observational analysis of MCTs performed in our center (Centre Hospitalier de l'Université de Montréal, Montréal, Canada) between October 2017 and May 2018. The study protocol was accepted by the local ethics board.

Subjects {#Sec3}
--------

All adult subjects being referred to the pulmonary physiology laboratory for MCT testing during the study period were considered for inclusion in the study. They were referred by their attending physician (either local respiratory medicine specialist, allergist, internist or out-of-hospital general practitioner) for an elective MCT in order to evaluate respiratory symptoms and/or suspected asthma. Patients were excluded if they were unable to complete spirometry and MCT according to current guidelines \[[@CR2]\].

Protocol {#Sec4}
--------

All MCTs were performed according to the American Thoracic Society guidelines using the 2-min tidal breathing dosing protocol \[[@CR2]\], with the exception of allowing the omission of the next methacholine dose up to a FEV~1~ fall of 10% from its previous value, rather than 5%. The initial methacholine dose which was chosen by the laboratory technician performing the test, based on each patient's pre-test probability for asthma, FEV~1~ change after diluent inhalation and basal FEV~1~ value. Each MCT was followed by inhalation of nebulized salbutamol (2.5 mg). A second salbutamol dose was administered if FEV~1~ did not return to \> 90% of FEV~1~ baseline value 10 min after the first dose. Medical files were reviewed to extract demographic data, presence of a history of asthma or atopy, use of inhaled medication and complete lung function test results. As per current guidelines, each step of the MCT lasted 5 min \[[@CR2]\].

Patients of interest were those in which a dose was skipped after a previous FEV~1~ fall that was outside the usual range of 5% ("skip~5--10%~"). Bronchial hyperresponsiveness (BHR) was considered present when CP~20~ was ≤ 8 mg/ml.

Outcomes {#Sec5}
--------

Outcomes of interest were the overall prevalence of skip~5--10%~, the prevalence of subjects in which a skip~5--10%~ directly led to the reaching of PC~20~ and adverse effects (AE). AE were categorized as mild: \> 1 nebulized salbutamol dose (2.5 mg) to reach basal FEV~1~, coughing, palpitations; or severe: hypoxemia and/or any need for immediate medical attention or intervention.

Statistical analysis {#Sec6}
--------------------

Data are presented as means (standard deviation), median (interquartile range) or n (percent), where appropriate. Comparison of variable between groups were performed using unpaired t-tests for continuous variables or Chi-squared tests for categorical variables. A multiple binary regression model was performed to identify independent predictors of the presence of AE. Sensitivity and specificity analyses of each variable of the regression model that showed an independent relationship to the presence of AE was performed, as well as receiver operating curve (ROC) analyses.

In all cases, a p-value ≤ 0.05 was used to identify statistical significance. Analyses were performed using SPSS v21 (IBM corporation).

Results {#Sec7}
=======

Population {#Sec8}
----------

A total of 212 MCT were reviewed, of which 208 were included for analysis. Four tests had to be excluded from the study because of the inability of the patients to adequately perform spirometry maneuvers. Baseline complete lung function tests were available for 186 patients (89%).

Table [1](#Tab1){ref-type="table"} describes the baseline characteristics of the study population, and the comparison between demographic and lung function testing values among patients with (n = 61) and without BHR (n = 147). Patients with BHR frequently used short-acting beta-agonist medication and had significantly lower values of FEV~1~/FVC, FEV~1~ and FVC, and higher values of RV (all p ≤ 0.05), suggesting more frequent airway obstruction and gas trapping in that group.Table 1Baseline patient characteristicsAllBHR presentBHR absentpn20861147Age52 (15)53 (17)51 (14)0.42Male sex135 (65)41 (67)94 (64)0.65BMI28 (6)29.2 (6.0)27.5 (6.0)0.07History of asthma60 (29)22 (37)38 (26)0.11Atopy110 (53)34 (62)76 (52)0.23Pharmacological treatment SABA75 (36)30 (51)45 (31)0.008 LABA2 (1)0 (0)2 (1)0.37 LAMA7 (3)4 (7)3 (2)0.09 ICS51 (25)18 (31)33 (23)0.25 ICS--LABA combination34 (16)9 (15)35 (17)0.73Lung function testing^a^ FEV~1~/FVC0.76 (0.07)0.73 (0.09)0.79 (0.06)\< 0.001 FEV~1~, l2.82 (0.77)2.55 (0.81)2.95 (0.72)0.001 FEV~1~, %95 (14)90 (15)98 (13)\< 0.001 FVC, l3.66 (0.95)3.45 (98)3.76 (0.92)0.04 FVC, %97 (13)96 (14)98 (12)0.24 RV, l1.86 (0.57)2.01 (0.70)1.79 (0.49)0.02 RV, %100 (25)111 (33)96 (19)\< 0.001 FRC, l2.85 (0.68)2.88 (0.75)2.83 (0.65)0.66 FRC, %96 (19)100 (23)94 (16)0.07 TLC, l5.61 (1.03)5.56 (1.00)5.63 (1.04)0.70 TLC, %102 (13)104 (14)102 (12)0.27 D~L~CO, %94 (19)92 (24)96 (17)0.24Methacholine challenge Starting dose, mg/ml1 (0.25--1)1 (0.25--1)1 (1--1)0.001 PC~20~, mg/ml^b^4.2 (1.5--6.8)2.2 (1.1--5.3)12.3 (10.0--14.1)\< 0.001Data presented as mean (standard deviation), median (interquartile range) or n (percent), where appropriateBHR is considered present when CP~20~ is ≤ 8 mg/ml*BHR* bronchial hyperresponsiveness, *BMI* body mass index, *SABA* short-acting beta-agonist, *LABA* long-acting beta-agonist, *LAMA* long-acting muscarinic antagonist, *ICS* inhaled corticosteroid, *FEV*~*1*~ forced expiratory volume in 1 s, *FVC* forced vital capacity, *RV* residual volume, *FRC* functional residual capacity, *TLC* total lung capacity, *DLCO* diffusion capacity of the lung for carbon monoxide^a^Data available for 186 patients^b^Mean for the "BHR absent" group based on 16 patients. PC~20~ was \> 16 mg/ml in the remaining 131 patients

Prevalence of skipped doses after FEV~1~ decrease by 5--10% (skip~5--10%~) {#Sec9}
--------------------------------------------------------------------------

Overall, there were 90 MCTs in which at least one skip~5--10%~ was performed (43%). Of these, 17 tests included 2 occurrences of skip~5--10%~ and 2 tests included 3 occurrences of skip~5--10%~, for a total of 111 skipped doses (Fig. [1](#Fig1){ref-type="fig"}). Overall, MCTs in which at least one skip~5--10%~ occurred had a lower mean number of doses (3.1 ± 0.6 vs. 3.5 ± 1.3 doses, p = 0.007). When considering the 131 subjects in which PC~20~ was not reached, this difference increased to 3.0 ± 0.1 vs. 4.0 ± 1.1 doses, p \< 0.001).Fig. 1Number of patients in which a skip~5--10~ did or did not occur

Adverse events {#Sec10}
--------------

Across the whole study population, a total of 11 AEs were reported (5%). All AEs were mild and consisted of the need to provide patients with an additional dose of SABA after the completion of the test due to an FEV~1~ value failing to reach its baseline value, most often accompanied by cough (8/11 cases). No severe AE occurred.

Table [2](#Tab2){ref-type="table"} reports patient characteristics according to the development of AE. Patients in which AE occurred had significantly lower resting pulmonary function values for FEV~1~/FVC, FEV~1~ and FVC and higher values of RV and TLC. However, the mean values of FEV~1~ and FVC remained in the normal range even in this group. In addition, the presence of an AE was associated with lower PC~20~, but not with the presence of a skip~5--10%~ (36% vs. 44%, p = 0.64). However, the presence of a skip~5--10%~ that led to the reaching of the PC~20~ was more frequent in the group that presented AEs (27% vs. 8%, p = 0.03).Table 2Patient characteristics according to the presence of adverse eventsAdverse eventNo adverse eventpn11197Age55 (14)52 (15)0.49Male sex7 (64)128 (65)0.93BMI28.3 (4.4)28.0 (6.1)0.87History of asthma5 (45)55 (28)0.14Atopy5 (45)105 (55)0.74Use of any inhaled medication8 (80)93 (48)0.05Lung function testing^a^ FEV~1~/FVC0.71 (0.41)0.79 (0.35)0.02 FEV~1~, %84 (14)96 (14)0.005 FVC, %80 (29)96 (13)0.001 RV, %141 (53)98 (20)\< 0.001 FRC, %116 (28)95 (17)\< 0.001 TLC, %110 (16)102 (12)0.06 D~L~CO, %92 (33)95 (19)0.66Methacholine challenge Starting dose, mg/ml1 (0.25--1)1 (0.25--1)0.46 PC~20~, mg/ml^b^2.4 (1.7)5.5 (4.4)0.03 Dose skipped after FEV~1~ decreased 5--10%4 (36)86 (44)0.64 Dose skipped after FEV~1~ decreased 5--10% and PC~20~ reached3 (27)16 (8)0.03 Number of skipped doses after FEV~1~ decreased 5--10%0 (0--1)0 (0--1)0.40Data presented as mean (standard deviation), median (interquartile range) or n (percent), where appropriate*FEV*~*1*~ forced expiratory volume in 1 s, *FVC* forced vital capacity, *RV* residual volume, *FRC* functional residual capacity, *TLC* total lung capacity, *DLCO* diffusion capacity of the lung for carbon monoxide^a^Data available for X patients^b^Data available for the 77 patients with PC~20~ \< 16 mg/ml

Prediction of the occurrence of adverse events {#Sec11}
----------------------------------------------

A multiple binary regression model was performed to identify independent predictors of the presence of an AE (Table [3](#Tab3){ref-type="table"}). Included variables were: use of any inhaled medication, baseline FEV~1~ (percent predicted), baseline RV (percent predicted) and the presence of a skip~5--10%~ that led to the reaching of the PC~20~. Of those, only RV (percent predicted) was significantly related to the development of an AE (OR 1.05, 95% CI 1.01--1.10, p = 0.01). Of note, the presence of skip~5--10%~ that led to the reaching of the PC~20~ was not an independent predictor of the presence of AE (OR 5.40, 95% CI 0.73--39.22, p = 0.10).

A receiver operating curve analysis (Fig. [2](#Fig2){ref-type="fig"}) revealed that a resting RV (percent predicted) value of \> 108% could predict the presence of an AE with a sensitivity and specificity of 90% and 78%, respectively (area under the curve 0.83, 95% CI 0.72--0.95, p \< 0.001).Fig. 2Receiver operating characteristic (ROC) curve evaluating the relationship between residual volume (at the optimal cut-off value of 108% predicted) and the presence of an adverse event during the test Table 3Multiple binary regression model for the identification of predictors of adverse eventsOdds ratio95% CIpAny inhaler medication0.500.06--3.810.50FEV~1~, *percent predicted*0.970.90--1.030.30RV, *percent predicted*1.051.01--1.100.01Dose skipped after FEV~1~ decreased 5--10% and PC~20~ reached5.400.73--39.220.10*FEV*~*1*~ forced expiratory volume in 1 s, *RV* residual volume

Discussion {#Sec12}
==========

To our knowledge, this study is the first to evaluate the feasibility and safety of using a threshold higher than 5% in FEV~1~ fall to allow dose-omission during MCT. Our main results can be summarized as follow: (1) the use of a 10% fall in FEV~1~ threshold to skip the next methacholine dose allowed shortening the test in a large proportion of our subjects, (2) the use of this threshold was generally safe, with only mild AE being reported and (3) resting lung function values, especially RV, were associated with the occurrence of AEs.

The safety of other time-saving methods, such as increasing the initial dose of methacholine and skipping doses whenever the FEV~1~ falls by \< 5% has been described several times. Troyanov et al. observed an incidence of exaggerated bronchoconstriction, defined as either a fall in FEV~1~ of \> 20% after saline or \> 30% after methacholine inhalation, of 10% in a group of 408 subjects, and skipped concentrations accounted for 12% of them (overall prevalence of 1%) \[[@CR5]\]. Cockroft et al. showed that, in a population of 380 subjects undergoing MCT, 11 of them had a fall in FEV~1~ \> 20% after a skipped concentration dose, but no cases of exaggerated bronchoconstriction, defined as a fall in FEV~1~ \> 40%, were observed after a skipped concentration \[[@CR3]\].

The use of rapid modern nebulizers may also be used to shorten inhalation time, time between the start of each inhalation and, eventually, total MCT time. However, these devices can be expensive, and are associated with lower PC~20~ values due to the cumulative effect of providing doses at a shorter interval \[[@CR9]--[@CR11]\].

The incidence of AEs in our study was low and comparable to the aforementioned safety data regarding the skipping of methacholine doses based on FEV~1~ fall, even though we used a larger threshold than the one of 5% usually reported.

Our finding that baseline function was related to the occurrence of AEs during the tests echoes the notion that baseline airway obstruction should help tailor certain MCT parameters (such as the methacholine starting dose) to individual patient's characteristics \[[@CR2], [@CR12]\]. Our results suggest that patients with overt baseline gas trapping (as measured with RV) and those with lower FEV~1~ and FEV~1~/FVC ratio had higher rates of AEs when using our protocol, although only RV was identified as an independent predictor of the presence of AEs. In clinical practice, the usefulness of these findings may seem limited because measurements of lung volumes are not always available before performing MCT. In addition, baseline FEV~1~ in our study remained in the normal range even in the group of patients with AEs, making a pre-test risk stratification difficult. Nonetheless, these results highlight the need for clinicians to use, whenever possible, baseline lung function data to decide whether or not to proceed with a skipping protocol such as ours.

Strengths of our study include the relatively large sample size that allowed for the inclusion of a wide spectrum of patients with various pre-test probability of asthma. The majority of our subjects had no history of airway hyperresponsiveness and only half had a history of atopy, which reflects the spectrum of patients being referred to our center both by general practitioners and specialists. Selection bias was attenuated by including all tests performed during the study period, excepted for a small number of cases where patients could not complete the MCT for technical reasons.

Our study also has weaknesses that need to be acknowledged. First, the absence of a control group (one in which a standard threshold of 5% fall in FEV~1~ would have been used to skip doses) precludes a direct comparison of the prevalence of AEs between those two protocols, and the direct comparison of our results with others from the literature \[[@CR5]\]. It remains, however, that our results support the safety and feasibility of our protocol in clinical practice. Also, the incidence of AEs was low, which may impair the statistical power of certain analyses, especially when aiming at identifying predictors of the occurrence of AEs. This low incidence of AEs may be related to the intrinsic safety of MCTs, but also to the prevalence of BHR in our cohort (29%). This prevalence is similar to some \[[@CR3]\], but lower than other \[[@CR8]\] studies performed in the clinical setting. Further prospective studies aiming at directly comparing the effects of using the 10% or 5% fall in FEV~1~ threshold to skip methacholine doses would help strengthen our results. In addition, studies investigating the effects of the simultaneous use of various time-saving procedures (tailoring of initial dose, threshold for dose-skipping, early termination of test) could eventually lead to an MCT protocol allowing more customization based on individual characteristics of each patient.

Conclusion {#Sec13}
==========

During MCT, the prevalence of the omission of the next methacholine dose based on a ≤ 10% fall in FEV~1~ is high, and shortens test duration. When using this protocol, AEs remain rare and mild, but are associated with greater baseline airway obstruction and gas trapping. These results suggest that the use of this threshold is both feasible, useful and safe, but further studies are needed on the effect of combining various time-saving modifications to the MCT protocol.
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